Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology | Family Medicine
 Disease Category: Peripheral Neuropathy
Location: United States, TX

Trial Information

A phase 3b multicenter, double-blind, efficacy and safety study of pregabalin in the treatment of patients with inadequately treated painful diabetic peripheral neuropathy (protocol A0081242)

IRB Number: 010-087

This is a phase 3, double-blind, efficacy and safety study of pregabalin in the treatment of patients with inadequately treated painful diabetic peripheral neuropathy

Inclusion Criteria:

  • Men or women, Type 1 or 2 diabetes
  • HbA1c less than 11%
  • Diagnosed with Diabetic Neuropathy
  • Must be on one(or combo of 2):
    • Tramadol
    • Gabapentin
    • Venlafaxine
    • Duloxetine
    • Trycyclic antidepresent

Exclusion Criteria:

  • Must not be on retinotoxin
    • Hydroxychloroquine
    • Deferosamine
    • Thioridazine
    • vigabatrin
  • Can not be on pregabalin (lyrica)

Priscilla Hollander, MD
Baylor Research Institute
3600 Gaston Ave, Wadley #656
Dallas, TX 75246
Phone: 214-818-7155

View Map

Research Center Information: Baylor Research Institute

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.